Clinical trials: Organ Transplant Recipients
Squamous Cell Carcinoma
Warning Signs of Squamous Cell Carcinoma and Prevention of SCC by at Risk Organ Transplant Recipients
Using focus group and cognitive interviews with organ transplant recipients, the investigators developed interactive workbooks: a) prevention by sun protection b) early detection by skin self-examination (SSE).
- Trial name
- SCCs in OTRs (NCT01127737)
- Testing
- Educational Intervention
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Northwestern University
Cytomegalovirus Disease
Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for Cytomegalovirus Infection
The purpose of the study is to assess the incidence and severity of late Cytomegalovirus (CMV) disease, defined as CMV syndrome or tissue invasive disease occurring between 100 and 200 days and after 200 days post-transplant in…
- Trial name
- NCT01509404
- Testing
- Valganciclovir, CMV hyperimmune globulin
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Medical University of South Carolina
Kidney Transplantation, Graft Rejection
Efficacy and Safety Study of Everolimus Plus Reduced Cyclosporine Versus Mycophenolic Acid Plus Cyclosporine in Kidney Transplant Recipients
The purpose of this study was to compare the safety and efficacy of three immunosuppressive treatment regimens following a kidney transplant.
- Trial name
- NCT00251004
- Testing
- Everolimus, Mycophenolic Acid (MPA), Cyclosporine A (CsA)
- Where
- United States
- Volunteers
- 833 people
- Sponsor
- Novartis
Clostridium Difficile Infection Recurrence
Fecal Microbiota Transplantation for C. Difficile Infection in Solid Organ Transplant Recipients
The objective is to examine the effect of Fecal Microbiota Transplantation (FMT) compared with vancomycin for cure of recurrent C.
- Trial name
- NCT03617445
- Testing
- FMT oral capsule, Oral Vancomycin
- Where
- 5 sites in United States
- Volunteers
- 3 people
- Sponsor
- University of Wisconsin, Madison
Hepatitis C, Kidney Transplant; Complications
A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant Recipients
This study is being done to determine the effectiveness of using a combination of two different drugs in preventing the transmission of HCV from a HCV positive donor to a HCV negative solid organ recipient.
- Conditions
- Hepatitis C, Kidney Transplant; Complications, Heart Transplant Infection
- Trial name
- NCT04508907
- Testing
- Mavyret
- Where
- United States
- Volunteers
- 227 people
- Sponsor
- Mayo Clinic
Kidney Transplantation
Combination Drug Therapy Followed by Single Drug Steroid Free Therapy to Prevent Organ Rejection in Kidney Transplantation
This study will test the safety and effectiveness of a combination of three drugs followed by long-term treatment with just one drug in preventing organ rejection in kidney transplant patients.
- Trial name
- NCT00076570
- Testing
- Sirolimus, Tacrolimus
- Where
- United States
- Volunteers
- 31 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Immunosuppression in Solid Organ Transplant
Belatacept in Liver Transplant Recipients
The purpose of this clinical research study is to evaluate the effects of belatacept, relative to tacrolimus, on the incidence of rejection, graft loss and death in subjects receiving a liver transplant
- Trial name
- NCT00555321
- Testing
- Tacrolimus, Basiliximab, Belatacept More Intensive (MI)
- Where
- 42 sites in United States, Argentina and 7 more
- Volunteers
- 260 people
- Sponsor
- Bristol-Myers Squibb
Cutaneous Squamous Cell Carcinoma, Advanced Cancer
Cemiplimab in AlloSCT/SOT Recipients With CSCC
In this research study, Cemiplimab is being evaluated as a treatment for advanced cutaneous squamous cell carcinoma in participants who have previously received an allogeneic hematopoietic stem cell transplant or kidney…
- Trial name
- CONTRAC (NCT04339062)
- Testing
- Cemiplimab, Everolimus, Sirolimus
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Dana-Farber Cancer Institute
Cytomegalovirus (CMV)
A Study of Maribavir in Japanese People With Cytomegalovirus (CMV) Infection
The main aim of the study is to check if maribavir can treat Japanese people with Cytomegalovirus (CMV) infection, and to check side effect from the study treatment and how much maribavir participants can take without getting…
- Trial name
- NCT05137717
- Testing
- Maribavir
- Where
- 20 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Takeda
Organ Transplantation
Belatacept Post Depletional Repopulation to Facilitate Tolerance
Acute rejection is a common problem after a kidney transplant. Rejection can occur when the kidney recipient's immune system tries to attack (or reject) the new kidney.
- Trial name
- NCT00565773
- Testing
- Belatacept, Sirolimus, Alemtuzumab
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Allan D Kirk, MD, PhD
Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder
Immunogenicity of Fluzone High Dose in Immunocompromised Children and Young Adults
The purpose of this study is to determine whether Fluzone High Dose increases the immune response to the influenza antigens contained in the vaccine compared to standard-dose Fluzone in immunocompromised children and young…
- Conditions
- Solid Organ Transplant Recipient (Liver, Kidney, Heart), Rheumatologic Disorder, Human Immunodeficiency Virus (HIV), Bone Marrow Transplant (BMT)
- Trial name
- NCT01685372
- Testing
- Fluzone High Dose, Fluzone
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of Colorado, Denver
Human Papilloma Virus, Hiv
Study of Safety, Tolerability and Immunogenicity of Gardasil®9 in Immunocompromised Patients
Patients with immunodeficiencies are at increased risk of developing persistent HPV infection and as such HPV-related disease (genital warts and cancer).
- Conditions
- Human Papilloma Virus, Hiv, Organ Transplants
- Trial name
- NCT03525210
- Testing
- 9-valent HPV vaccine
- Where
- Belgium
- Volunteers
- 271 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Gel 0.015% for Treatment of AK on the Face in Solid Organ Transplant Recipients
This is a single arm, open-label interventional study of ingenol mebutate 0.015% in solid organ transplant recipients. The investigators plan to treat 20 subjects, 10 kidney transplant recipients and 10 lung transplant…
- Trial name
- NCT02866695
- Testing
- ingenol mebutate gel 0.015%
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
Kidney Transplantation Cytomegalovirus (CMV) Negative Recipients
A Study to Evaluate the Efficacy and Safety of a Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seronegative Kidney Transplant Recipients Receiving an Organ From a CMV-Seropositive Donor
The purpose of this study was to evaluate the efficacy of ASP0113 compared to placebo in reducing the incidence of cytomegalovirus (CMV) viremia in CMV-seronegative subjects receiving a kidney from a CMV-seropositive donor.
- Trial name
- NCT01974206
- Testing
- ASP0113
- Where
- 53 sites in United States, Australia and 4 more
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Transplant Rejection, Renal Transplantation
Study To Evaluate Pharmacokinetics Of Sirolimus In Stable Renal Transplant Recipients
Sirolimus, 1 mg, white, triangular tablets (Rapamune®) was approved on 03 April 2007 in China for prophylaxis of organ rejection in renal transplantation.
- Trial name
- NCT01236378
- Testing
- Sirolimus
- Where
- 2 sites in China
- Volunteers
- 24 people
- Sponsor
- Pfizer
Organ Transplantation, Renal Transplantation
Everolimus in a Cyclosporine Microemulsion-free Regimen Compared to a Low-dose Cyclosporine Microemulsion Regimen, in de Novo Kidney Transplant Patients
The purpose of this study is to evaluate the safety and efficacy of everolimus in combination with basiliximab, and steroids with and without cyclosporine microemulsion in de novo kidney transplant recipients.
- Trial name
- CERTES02 (NCT00154284)
- Testing
- Everolimus (Certican), Cyclosporine (Neoral), Steroid
- Volunteers
- 114 people
- Sponsor
- Novartis
EBV Viremia, CMV Viremia
Treating Kidney Donors With Valganciclovir to Reduce Viral Transmission to Recipients
The aim of our study is to reduce viral (CMV and EBV) transmission from donor to recipient. The discovery that anti-retroviral therapy to mothers with HIV reduced transmission of the virus to their babies was pivotal to the…
- Trial name
- NCT01329185
- Testing
- Valganciclovir
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Minnesota
EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder
Rituximab and LMP-Specific T-Cells in Treating Pediatric Solid Organ Recipients With EBV-Positive, CD20-Positive Post-Transplant Lymphoproliferative Disorder
This pilot phase II trial studies how well rituximab and latent membrane protein (LMP)-specific T-cells work in treating pediatric solid organ recipients with Epstein-Barr virus-positive, cluster of differentiation…
- Conditions
- EBV-Related Post-Transplant Lymphoproliferative Disorder, Monomorphic Post-Transplant Lymphoproliferative Disorder, Polymorphic Post-Transplant Lymphoproliferative Disorder, Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder
- Trial name
- NCT02900976
- Testing
- Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes, Rituximab
- Where
- 38 sites in United States
- Volunteers
- 18 people
- Sponsor
- Children's Oncology Group
Kidney Transplant, Liver Transplant
A Cohort Study of Operationally Tolerant Allograft Recipients
Antirejection medicines, also known as immunosuppressive drugs, are prescribed to organ transplant recipients to prevent their bodies from rejecting the new organ.
- Trial name
- ALLTOL (NCT02743793)
- Testing
- Blood Draw
- Where
- 5 sites in United States
- Volunteers
- 41 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Infection in Solid Organ Transplant Recipients
Valganciclovir Dosing in Pediatric Solid Organ Transplant Recipients
Valganciclovir is extensively used for cytomegalovirus (CMV) infection treatment and prophylaxis after solid organ transplantation (SOT). VGC dosing is problematic in children.
- Trial name
- NCT02503982
- Testing
- prophylactic Valganciclovir
- Where
- Israel
- Volunteers
- 13 people
- Sponsor
- Rabin Medical Center